PMC:4197335 / 36676-37728 JSONTXT

{"project":"2_test","denotations":[{"id":"25314077-21968997-17318441","span":{"begin":564,"end":568},"obj":"21968997"},{"id":"25314077-17657224-17318442","span":{"begin":749,"end":753},"obj":"17657224"}],"text":"Animal Studies\nMice were housed in the animal facilities at Hammersmith. All experiments were conducted under Procedure Project License (PPL) 70/6874, after approval by the Imperial College Ethical Review Process and the Home Office. For the plasmacytoma model, nonobese diabetic/severe combined immunodeficiency mice (NOD.CB17-Prkdcscid/IcrCrl; Charles River) were injected subcutaneously with 1.0 × 107 U266 or KMS-11 MM cells and then randomized into treatment groups and treated by infusion, as shown. Tumor volumes were measured as described by Mauro et al. (2011). For the orthotopic MM model, mice of the same strain were sublethally irradiated and then injected intravenously with 1.0 × 107 KMS-12-BM MM cells, as described by Rabin et al. (2007). Mice were then randomized into treatment groups and treated by infusion for 8 weeks, as shown. Animals were monitored daily and euthanized on day 161 of treatment start or when they reached any of the end points in the PPL. Additional details are provided in Supplemental Experimental Procedures."}